Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
Lyra Therapeutics (Nasdaq: LYRA) outlined a clinical plan for LYR-210…
Browsing Category